12.02USD-0.95%Mkt Cap: 318.04M USDP/E: —Last update: 2026-05-26
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II c…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap318.04M USD
Enterprise Value181.29M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-52.60M USD
Revenue/Share—
Last Price12.02 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS88032L5066
Valuation
P/E (Trailing)—
P/E (Forward)-8.77
PEG1.44
EV/EBITDA—
EV/Revenue—
P/S—
P/B5.40
EPS (TTM)-1.41
EPS (Forward)-1.41
52W Range
5.34051% of range18.38
52W High18.38 USD
52W Low5.340 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.19%
ROA-50.47%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.80M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-118.75M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio14.52
Quick Ratio13.99
Book Value/Sh2.288 USD
Cash/Share4.892 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 26, 2018
Splits
Last Split1:80
Split DateJan 3, 2024
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)29.71 USD
Target Range20.00 USD – 36.00 USD
# Analysts7
Ownership
Shares Out.26.53M
Float10.61M
Insiders0.12%
Institutions84.40%
Short Interest
Short Ratio1.3d
Short % Float2.87%
Short % Out.2.83%
Shares Short730.70K
Short (prev mo.)172.74K
Technical
SMA 5013.73 (-12.5%)
SMA 20010.53 (+14.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)618.85K
Avg Vol (10d)633.61K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—